Pharmaceuticals News and Research

RSS

Veloxis seeks EMA approval to market LCP-Tacro for kidney transplant patients

Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.

29 Apr 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection.

29 Apr 2013

Shin Poong to develop, market Almac Discovery's ALM201 in South Korea

Almac Discovery today announced the licensing of its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Company Ltd for clinical development and marketing in South Korea.

29 Apr 2013

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.

29 Apr 2013

Prescription drug 'track and trace' bill splits House lawmakers

House lawmakers are split on how the federal government should better track prescription drugs with one powerful Republican promising a "track and trace" law by August while Democrats press for stronger safeguards in the proposal.

29 Apr 2013

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila.

29 Apr 2013

Protein C4BP is possibly suitable as transporter for drugs, say researchers

The protein C4BP is similar to a spider in its spatial form with eight "arms". The structure of the "spider body" has recently been described in detail by researchers from the Helmholtz Centre for Infection Research in Braunschweig and the Technische Universit-t Darmstadt.

29 Apr 2013

Doctors assail drugmakers for $100K cancer medicines

More than 100 cancer specialists call for pharmaceutical companies to lower the prices of these drugs that patients need to live.

29 Apr 2013

Actavis resolves patent litigation related to generic version of INTUNIV for treatment of ADHD

Actavis, Inc., a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with Shire plc resolving outstanding patent litigation related to Actavis' generic version of INTUNIV® (guanfacine hydrochloride) for the treatment of Attention Deficit Hyperactivity Disorder.

26 Apr 2013

Ampio completes patient enrollment in dose-escalation run-in study of Ampion for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.

26 Apr 2013

Examining social factors is vital to understand the rise in diagnoses of mental disorders

Examining social factors is vital to better explaining and understanding the dramatic rise in the number of Americans diagnosed with mental disorders in recent years, according to an analysis by a team of medical and mental health experts.

26 Apr 2013

Derma Sciences initiates patient screening in DSC127 pivotal program for treatment of diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers.

26 Apr 2013

Simulations Plus to distribute quarterly cash dividend in May 2013

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute a cash dividend in May.

26 Apr 2013

First Edition: April 26, 2013

Today's headlines include reports that some Democratic senators have concerns about the health law's roll out as well as other news about the measure's implementation.

26 Apr 2013

Covidien net sales increase 5% to $3.10 billion in second quarter 2013

Covidien plc today reported results for the second quarter of fiscal 2013 (January - March 2013). Second-quarter net sales of $3.10 billion increased 5% from the $2.95 billion reported in the second quarter a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by two percentage points.

26 Apr 2013

Thermo Fisher Scientific brings several innovations in bioprocessing technologies and systems

Thermo Fisher Scientific Inc., the world leader in serving science, today debuted several innovations in bioprocessing technologies and systems that address the evolving requirements of drug discovery and production for global biopharmaceutical and pharmaceutical manufacturers.

From Thermo Fisher Scientific Inc. 26 Apr 2013

New Haven Pharmaceuticals gets venture loan facility from Horizon Technology Finance

Horizon Technology Finance Corporation ("Horizon"), a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and clean-tech industries, today announced it has closed a $2 million venture loan facility with New Haven Pharmaceuticals, Inc. ("NHP"), a developer of prescription pharmaceuticals that utilize currently marketed drugs or active pharmaceutical ingredients generally recognized as safe for use in therapeutic applications.

26 Apr 2013

Increasing unsustainable prices for leukemia drugs represent larger issue across all cancers

The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and published online today in Blood, the Journal of the American Society of Hematology (ASH).

26 Apr 2013

Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr. Jennifer Cohn, Médecins Sans Frontières

MDR-TB is tuberculosis, a mycobacterial infection, that has developed resistance to two important and powerful first-line anti-TB drugs, INH and rifampin.

26 Apr 2013

Cempra reports net loss of $10.3 million in first quarter 2013

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2013.

26 Apr 2013

Pharmaceuticals News and Research

Veloxis seeks EMA approval to market LCP-Tacro for kidney transplant patients

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Shin Poong to develop, market Almac Discovery's ALM201 in South Korea

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Prescription drug 'track and trace' bill splits House lawmakers

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Protein C4BP is possibly suitable as transporter for drugs, say researchers

Doctors assail drugmakers for $100K cancer medicines

Actavis resolves patent litigation related to generic version of INTUNIV for treatment of ADHD

Ampio completes patient enrollment in dose-escalation run-in study of Ampion for treatment of knee osteoarthritis

Examining social factors is vital to understand the rise in diagnoses of mental disorders

Derma Sciences initiates patient screening in DSC127 pivotal program for treatment of diabetic foot ulcers

Simulations Plus to distribute quarterly cash dividend in May 2013

First Edition: April 26, 2013

Covidien net sales increase 5% to $3.10 billion in second quarter 2013

Thermo Fisher Scientific brings several innovations in bioprocessing technologies and systems

New Haven Pharmaceuticals gets venture loan facility from Horizon Technology Finance

Increasing unsustainable prices for leukemia drugs represent larger issue across all cancers

Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr. Jennifer Cohn, Médecins Sans Frontières

Cempra reports net loss of $10.3 million in first quarter 2013

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence